Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
暂无分享,去创建一个
[1] R. Jordan,et al. Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages , 2015, The Journal of Immunology.
[2] M. Lindorfer,et al. Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. , 2015, Blood.
[3] Ronald P. Taylor,et al. Analyses of CD20 Monoclonal Antibody–Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies , 2014, Molecular Pharmacology.
[4] S. Ram,et al. The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells , 2014, mAbs.
[5] A. Ardizzoni,et al. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance , 2014, Molecular Cancer.
[6] C. Klein,et al. Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity , 2014, The Journal of Immunology.
[7] P. Kubes,et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. , 2014, The Journal of clinical investigation.
[8] Sally E. Ward,et al. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells , 2013, mAbs.
[9] P. Bousso,et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. , 2013, The Journal of clinical investigation.
[10] C. Klein,et al. Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models , 2013, Molecular Cancer Therapeutics.
[11] D. Davis,et al. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. , 2013, Blood.
[12] H. Harigae,et al. Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand , 2013, Proceedings of the National Academy of Sciences.
[13] Jens-Peter Volkmer,et al. Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response , 2013, Proceedings of the National Academy of Sciences.
[14] S. Jung,et al. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity. , 2013, ACS chemical biology.
[15] R. Jordan,et al. Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function , 2012, The Journal of Immunology.
[16] S. Ram,et al. 3D single molecule tracking with multifocal plane microscopy reveals rapid intercellular transferrin transport at epithelial cell barriers. , 2012, Biophysical journal.
[17] J. Ravetch,et al. Mouse model recapitulating human Fcγ receptor structural and functional diversity , 2012, Proceedings of the National Academy of Sciences.
[18] J. Jansen,et al. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. , 2012, Immunology letters.
[19] G. Pietersz,et al. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond , 2012, Nature Reviews Drug Discovery.
[20] P. Parren,et al. Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells , 2011, The Journal of Immunology.
[21] P. Mero,et al. Dynamics of Macrophage Trogocytosis of Rituximab-Coated B Cells , 2011, PloS one.
[22] Ash A. Alizadeh,et al. Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.
[23] H. Komatsu. [Antibody therapy in cancer]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.
[24] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[25] E. Joly,et al. The Direction of Plasma Membrane Exchange between Lymphocytes and Accessory Cells by Trogocytosis Is Influenced by the Nature of the Accessory Cell , 2010, The Journal of Immunology.
[26] D. Davis. Mechanisms and functions for the duration of intercellular contacts made by lymphocytes , 2009, Nature Reviews Immunology.
[27] A. Sica,et al. M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro1 , 2009, The Journal of Immunology.
[28] M. Lindorfer,et al. Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving1 , 2008, The Journal of Immunology.
[29] J. Desjarlais,et al. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells , 2008, Molecular Cancer Therapeutics.
[30] J. Xiang,et al. Intercellular Trogocytosis Plays an Important Role in Modulation of Immune Responses , 2008, Cellular and Molecular Immunology.
[31] G. A. Lazar,et al. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. , 2007, Drug discovery today.
[32] J. Stavenhagen,et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. , 2007, Cancer research.
[33] Zhuo Gan,et al. Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy , 2007, Proceedings of the National Academy of Sciences.
[34] Michael E. Williams,et al. Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia1 , 2006, The Journal of Immunology.
[35] S. Krause,et al. Ex Vivo-activated Human Macrophages Kill Chronic Lymphocytic Leukemia Cells in the Presence of Rituximab: Mechanism of Antibody-dependent Cellular Cytotoxicity and Impact of Human Serum , 2006, Journal of immunotherapy.
[36] J. Ravetch,et al. Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.
[37] S. Ram,et al. Simultaneous imaging of different focal planes in fluorescence microscopy for the study of cellular dynamics in three dimensions , 2004, IEEE Transactions on NanoBioscience.
[38] M. Sliwkowski,et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.
[39] Raimund J. Ober,et al. Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn1 , 2004, The Journal of Immunology.
[40] E. Joly,et al. What is trogocytosis and what is its purpose? , 2003, Nature Immunology.
[41] Hyun-soo Cho,et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab , 2003, Nature.
[42] Brian Higgins,et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.
[43] R. Michel,et al. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] M. Jackson,et al. TCR-Mediated internalization of peptide-MHC complexes acquired by T cells. , 1999, Science.
[45] S. Ho,et al. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. , 1989, Gene.
[46] S. Silverstein,et al. Studies on the mechanism of phagocytosis. II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes , 1976, The Journal of experimental medicine.
[47] M. Raff,et al. Redistribution and pinocytosis of lymphocyte surface immunoglobulin molecules induced by anti-immunoglobulin antibody. , 1971, Nature: New biology.
[48] Ira Mellman,et al. Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.
[49] C. Harding,et al. Pathways of antigen processing. , 1991, Current opinion in immunology.
[50] D. Scheinberg,et al. Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.